





FAX Completed Form To 1.833.404.2392

Prescriber Help Desk 1.833.587.2012

Online

covermymeds.com/main/ prior-authorization-forms/

Request for Prior Authorization TESTOSTERONE PRODUCTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	F	Patient name			DC)B						
Patient address												
Provider NPI		Prescriber name			Ph	one						
Prescriber address					Fa	X						
Pharmacy name	Address					Phone						
Prescriber must complete all info	ormatio	ion above. It must be legible, correct, and	comple	ete or	form	will	be re	eturi	ned.			
Pharmacy NPI		Pharmacy fax	NDC	OC .								

Prior authorization is required for testosterone products. Payment will be considered with documentation of a specific testicular or hypothalamic/pituitary disease (primary hypogonadism or hypogonadotropic hypogonadism) that results in classic hypogonadism. Requests for FDA approved indications other than hypogonadism will not be subject to prior authorization criteria with adequate documentation of diagnosis. Payment for non-preferred testosterone products will be authorized only for cases in which there is documentation of previous trials and therapy failures with two preferred agents. Requests for erectile dysfunction, infertility, and age-related hypogonadism will not be considered. Payment will be considered under the following conditions:

- 1) Patient is male and 18 years of age or older (or 12 years of age and older for testosterone cypionate); and
- 2) Patient has two (2) morning pre-treatment testosterone levels below the lower limit of the normal testosterone reference range of the individual laboratory used (attach results); and
- 3) Patient has primary hypogonadism or hypogonadotropic hypogonadism (further defined below)
 - Primary hypogonadism (congenital or acquired) caused by testicular failure due to one of the following: cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, toxic damage from alcohol or heavy metals
 - Hypogonadotropic hypogonadism: idiopathic gonadotropin or luteinizing hormone-releasing (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation
- 4) Patient does not have:
 - Breast or prostate cancer
 - Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL
 - Hematocrit > 50%
 - Untreated severe obstructive sleep apnea
 - Severe lower urinary tract symptoms
 - Uncontrolled or poorly controlled heart failure

If criteria for coverage are met, initial authorizations will be given for 3 months. Requests for continuation of therapy will require the following:

- An updated testosterone level (attach result); and
- Documentation the patient has not experienced a hematocrit > 54% or an increase in PSA > 1.4ng/mL in the past 12 months.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

10/20 Page 1 of 2







1.833.404.2392 **Prescriber Help Desk**

FAX Completed Form To

1.833.587.2012

Online covermymeds.com/main/

prior-authorization-forms/

Request for Prior Authorization TESTOSTERONE PRODUCTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Preferred	Non-Preferred			·		
☐ Androderm	☐ Androgel		Fortesta	☐ St	riant	☐ Testred
☐ Testosterone Cypionate	☐ Android		Jatenzo	□ Te	estim	
☐ Testosterone Enanthate	☐ Aveed		Methitest	□ Te	estosterone	e Gel 1.62% Uogelxo
☐ Testosterone Gel 1% Packets	s ☐ Axiron		Methyltesto	osterone 🔲 To	estosterone	e Gel Pump
	☐ Depo-Testo	sterone	Natesto	T	estosteron	e Topical Solution
Strongth Dog		_		Quantity		Dava Sumply
Strength Dosa	age Instructions			Quantity	y	Days Supply
Complete for diagnosis of hypogo	nadism:					
 □ Primary Hypogonadism (congeni □ Cryptorchidism □ Bilatera □ Klinefelter's syndrome □ 0 □ Other: 	I torsion	chitis	anishing test	tes syndrome ohol or heavy m	☐ Orchiect	omy
☐ Hypogonadotropic Hypogonadisn	ղ։					
☐ Idiopathic gonadotropin or lute		eleasing (LHR	H) deficienc	у		
☐ Pituitary-hypothalamic injury fr	om tumors, traum	a, or radiation	·			
Please indicate setting in which m List & attach results of two (2) moreference range of the individual latevel 1: Da	ning pre-treatme	nt testostero	ne levels be	elow the lower	limit of the	
Does patient have any of the follow Breast or prostate cancer:	ving:	☐ Yes	☐ No			
Palpable prostate nodule or prostate-	-specific antigen (F	_	_	☐ Yes	□ No	
Hematocrit > 50%:	1 3 (Yes	☐ No			
Untreated severe obstructive sleep a	pnea:	Yes	☐ No			
Severe lower urinary tract symptoms	:	☐ Yes	☐ No			
Uncontrolled or poorly controlled hea	rt failure:	☐ Yes	☐ No			
Renewal Requests:						
List & attach updated testosterone level: Level:						
List & attach updated testosterone	level: Level:			_ Date:		
List & attach updated testosterone Has patient experienced the follow		? months:		_ Date:		
·		? months:	Most rec			
Has patient experienced the follow	ring in the past 12			ent lab date:		
Has patient experienced the follow Hematocrit > 54%:	ring in the past 12	☐ No ☐ No	Most red	ent lab date: ent lab date:		
Has patient experienced the follow Hematocrit > 54%: Increase in PSA > 1.4ng/mL:	ring in the past 12 Yes Yes Yes	□ No □ No	Most red	ent lab date: ent lab date:		

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.